Ng Chen Seng, Stobart Christopher C, Luo Honglin
Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, Canada.
Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, Canada.
Rev Med Virol. 2021 Sep;31(5):1-22. doi: 10.1002/rmv.2206. Epub 2021 Jan 7.
Severe acute respiratory syndrome coronavirus-2 is the etiological agent of the ongoing pandemic of coronavirus disease-2019, a multi-organ disease that has triggered an unprecedented global health and economic crisis. The virally encoded 3C-like protease (3CL ), which is named after picornaviral 3C protease (3C ) due to their similarities in substrate recognition and enzymatic activity, is essential for viral replication and has been considered as the primary drug target. However, information regarding the cellular substrates of 3CL and its interaction with the host remains scarce, though recent work has begun to shape our understanding more clearly. Here we summarized and compared the mechanisms by which picornaviruses and coronaviruses have evolved to evade innate immune surveillance, with a focus on the established role of 3C in this process. Through this comparison, we hope to highlight the potential action and mechanisms that are conserved and shared between 3C and 3CL . In this review, we also briefly discussed current advances in the development of broad-spectrum antivirals targeting both 3C and 3CL .
严重急性呼吸综合征冠状病毒2是正在流行的2019冠状病毒病的病原体,这是一种多器官疾病,引发了前所未有的全球健康和经济危机。病毒编码的3C样蛋白酶(3CL),因其在底物识别和酶活性方面与小核糖核酸病毒3C蛋白酶(3C)相似而得名,对病毒复制至关重要,被视为主要药物靶点。然而,关于3CL的细胞底物及其与宿主相互作用的信息仍然匮乏,尽管最近的研究开始让我们的理解更加清晰。在此,我们总结并比较了小核糖核酸病毒和冠状病毒为逃避先天免疫监视而进化出的机制,重点关注3C在此过程中已确立的作用。通过这种比较,我们希望突出3C和3CL之间保守和共有的潜在作用及机制。在本综述中,我们还简要讨论了针对3C和3CL的广谱抗病毒药物开发的当前进展。